Navigation Links
New study on popular prostate cancer protein provides insight into disease progression
Date:6/25/2013

LOS ANGELES (June 25, 2013) Researchers at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute have uncovered for the first time the vital role a popular protein plays in the stroma, the cell-lined area outside of a prostate tumor.

Researchers have long understood the function of the protein, Caveolin-1 (Cav-1), in prostate cancer, including its role in treatment resistance and disease aggressiveness. However, prior to this study, little was known about the role of Cav-1 within the stroma.

The study, published in the Journal of Pathology, found that a decreased level of the Cav-1 protein in the stroma indicated tumor progression a function opposite to the known role of Cav-1 within a tumor. Inside the tumor, an increased level of this protein signifies tumor progression. These human tumor findings suggest that patients whose prostate tumor is surrounded by a stroma with decreased levels of the Cav-1 protein may have an overall worse prognosis and a higher chance of disease relapse.

"How a prostate tumor communicates with its microenvironment, or stroma, is a vital process we need to understand to assess the aggressiveness of a patient's disease and potential response to treatment," said Dolores Di Vizio, MD, PhD, associate professor in the Urologic Oncology Research Program and senior investigator of the study. "This research suggests that the cells surrounding a prostate tumor are equally as important as the tumor itself in helping understand the complexity of a man's disease. This early-stage research may provide a new, future marker that may ultimately aid diagnosis and treatment, and personalize prostate cancer therapy."

In addition to understanding the role of Cav-1 in the tumor microenvironment, researchers discovered that the loss of Cav-1 causes an increase of cholesterol in the stroma. Previous research findings suggest that cholesterol levels are related to aggressive prostate cancer, but cholesterol's role had never been evaluated within the stroma.

"Cholesterol has been shown to be a driver of prostate cancer progression," said Di Vizio. "For the first time in prostate cancer research, we found that when levels of Cav-1 decrease in the stroma, both cholesterol and androgens increase. This finding may partly explain a resistance to traditional treatments."

Though the findings are preliminary, the Cedars-Sinai researchers Di Vizio, Michael Freeman, PhD, vice chair of research in the Department of Surgery and professor/director of the Cancer Biology Program at the Samuel Oschin Comprehensive Cancer Institute, and post-doctoral fellows Matteo Morello, PhD, and Sungyong You, PhD, will continue evaluating the role of the Caveolin-1 protein in the stroma and its potential end benefit in patients.


'/>"/>

Contact: Cara Lasala
cara.lasala@cshs.org
310-423-7798
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Study finds dramatic increase in hospitalization of US children with inflammatory bowel disease
2. GAP-AF study helps to define optimal approach to ablation
3. New Study: Alcohol Drinkers May Face Long Term Health Issues
4. A Study Shows That Mom’s Obesity Surgery May Help Break Cycle in Obese Kids
5. New Study Casts Doubt on FDA Pradaxa Conclusions
6. Results of landmark 11-year study on weight losss effect on heart disease risks published today
7. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
8. JAAOS Study Exposes Importance of Child Safety Seats for Children between Four and Eight – Kiley Law Group, LLC
9. Renowned Hudson Valley ENT Sleep Specialist Selected to Participate in FDA Study of New Obstructive Sleep Apnea Treatment
10. SMU researcher receives Hogg Foundation grant to study childhood depression
11. Depression screening in AF Clinics recommended by study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
Breaking Medicine Technology: